Success with ipilimumab in prostate cancer patients

Success with ipilimumab in prostate cancer patients

Two Mayo Clinic patients whose prostate cancer had been considered inoperable are now cancer free thanks in part to an experimental drug therapy that was used in combination with standardized hormone treatment and radiation therapy.

The men were participating in a clinical trial of an immunotherapeutic agent called MDX-010 or ipilimumab.

In these two cases, physicians say the approach initiated the death of a majority of cancer cells and caused the tumors to shrink dramatically, allowing surgery. In both cases, the aggressive tumors had grown well beyond the prostate into the abdominal areas.

"The goal of the study was to see if we could modestly improve upon current treatments for advanced prostate cancer," says Eugene Kwon, M.D., Mayo Clinic urologist and leader of the clinical trial. "The candidates for this study were people who didn't have a lot of other options. However, we were startled to see responses that far exceeded any of our expectations."

The patients first received a type of hormone therapy called androgen ablation, which removes testosterone and usually causes some initial reduction in tumor size. Researchers then introduced a single dose of ipilimumab, an antibody, which builds on the anti-tumor action of the hormone and causes a much larger immune response, resulting in massive death of the tumor cells. Both men experienced consistent drops in their prostate specific antigen (PSA) counts over the following weeks until both were deemed eligible for surgery. Then, during surgery, came a greater surprise.

"The tumors had shrunk dramatically," says Michael Blute, M.D., Mayo urologist, co-investigator and surgeon, who operated on both men. "I had never seen anything like this before. I had a hard time finding the cancer. At one point the pathologist (who was working during surgery) asked if we were sending him samples from the same patient."

One patient underwent radiation therapy after surgery; both have resumed their regular lives. Further research is being planned to understand more about the mechanisms of the antibody and how best to use the approach in practice. The researchers, however, note the significance of their findings.

"This is one of the holy grails of prostate cancer research," says Dr. Kwon. "We've been looking for this for years."

(Editor compiled and published Success with ipilimumab in prostate cancer patients at HealthNewsTrack on June 21, 2009 sourced from Mayo Clinic -

Prostate Cancer - recent articles and current news stories:

- Provenge - Sipuleucel-T may have added benefit in prostate cancer
- ADT with docetaxel extends survival in metastatic prostate cancer
- Prostate chronic inflammation increases prostate cancer risk
- Melatonin may lower advanced prostate cancer risk
- Prostate cancer - A change in circulating tumor cells detection has high potential in the prediction

Most related articles:

- Success with ipilimumab in prostate cancer patients
- Ipilimumab demonstrates improved survival in metastatic melanoma - 8.2
- Prostate chronic inflammation increases prostate cancer risk - 7
- Prostate cancer family history has no impact on treatment - 6
- Prostate cancer risk from heavy drinking - 5.9

More related articles:

- Ipilimumab, Prostate cancer, Hormone treatment, Radiation therapy, Clinical trial, Tumor, Prostate, Cancer
- $9 million grant for prostate cancer research - 17.2
- Acupuncture relieves hot flashes from prostate cancer treatment - 16.5
- Dietary supplements discouraged for prostate cancer patients - 16.3
- Prostate cancer family history has no impact on treatment - 16.1

Prostate Cancer related articles:

- Prostate chronic inflammation increases prostate cancer risk - 7
- Prostate cancer risk from heavy drinking - 5.9
- High insulin level increases prostate cancer risk - 5.9
- Early onset baldness may raise prostate cancer risk in African American men - 5.9
- Circumcision may protect you against prostate cancer - 5.8

Prostate Cancer article/news source:

Read more health articles from Mayo Clinic and health articles from USA.

Prostate Cancer - search related terms:

Cancer, Clinical trial, Hormone treatment, Ipilimumab, Prostate, Prostate cancer, Radiation therapy, Tumor,
Health Newstrack is dedicated to serve recent and updated health & medical research, events/news, views/reviews to its subscribers and free access to general public, health & medical professionals, and other health seekers worldwide online with a user-friendly system. Track health news daily at Health Newstrack.
Subscribe: rss | email

Top sections:
Health (189)
Breast cancer (169)
Healthcare (134)
HIV (130)
Obesity (126)
Pregnancy (115)
Diabetes (102)
Swine Flu (97)
Prostate Cancer (86)
Heart disease (86)
Smoking (81)
Alzheimer's Disease (79)
Cancer (75)
Depression (61)
Autism (53)

Current news
Mayo researchers: Dramatic outcomes in prostate cancer study - Success with ipilimumab or MDX-010 in prostate cancer patients

What is Prostate Cancer?
About Prostate Cancer -- Prostate cancer is a malignancy of one of the major male sex glands, in which cells of the prostate become abnormal and start to grow uncontrollably, forming tumors.

List health news, Health organizations, Health news world, Glossary     Go to top

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. We comply with the HONcode principles for trustworthy health information, and Health News Track is hon code accredited, verify here.
About us, Site map Privacy policy, Disclaimer
© 2015
Health Newstrack - Track Health News Daily at Our Newstrack on Health News provides latest health news, medical news, and health articles with recent health & medical updates.